经导管二尖瓣缘对缘修复术后跨二尖瓣压差与残余反流对预后的影响
本研究基于2360例功能性二尖瓣反流患者,分析M-TEER术后出院的超声心动图指标。结果显示跨二尖瓣平均压差每增加1 mmHg,主要终点风险独立增加10%,而轻度或中度残余反流伴低压差者预后更佳。
要点
- M-TEER术后TMPG每升高1 mmHg,全因死亡或心衰住院风险增加10%。
- 残余MR≤轻度且TMPG<5 mmHg者主要终点发生率最低(28.4%)。
- 中度残余MR伴TMPG<5 mmHg与MR≤轻度且TMPG<5 mmHg的预后无显著差异。
核心结论
- 在功能性二尖瓣反流患者中,M-TEER术后TMPG升高与主要终点风险增加独立相关。
- 轻度或中度残余MR伴低TMPG与更 favorable 的预后相关,提示平衡MR减少与TMPG可能有助于优化风险分层。
研究设计与样本
- 多中心注册研究(日本瓣膜性心脏病治疗与预后注册研究,UMIN000023653),纳入2360例功能性二尖瓣反流患者。
- 采用出院后超声心动图评估,根据残余MR严重程度和TMPG将患者分为5组。
- 主要终点为全因死亡或心力衰竭住院。
主要发现
- 2年主要终点事件率随TMPG升高而递增,从1 mmHg时的25.0%升至6 mmHg时的47.0%。
- 多变量分析显示TMPG每增加1 mmHg与主要终点独立相关(HR: 1.10; 95% CI: 1.02-1.17; P = 0.008)。
- 以MR≤轻度为参照,中度MR与风险升高无关,而MR>中度仍是主要终点的显著预测因素。
- 5组主要终点发生率分别为28.4%、39.0%、33.0%、43.7%、48.4%(P < 0.001),MR≤轻度且TMPG<5 mmHg组最低。
- 中度MR且TMPG<5 mmHg与MR≤轻度且TMPG<5 mmHg组的事件风险无显著差异(HR: 1.13; 95% CI: 0.92-1.41; P = 0.24)。
关键数值与推荐
- 分组标准:MR≤轻度且TMPG<5 mmHg(n=1,702);MR≤轻度且TMPG≥5至<10 mmHg(n=164);中度MR且TMPG<5 mmHg(n=361);中度MR且TMPG≥5至<10 mmHg(n=71);MR>中度或TMPG 10 mmHg(n=62)。
- 未达到MR≤轻度且TMPG<5 mmHg与较大的左房容积指数、较大的有效反流口面积、较高的基线TMPG和使用老一代G2装置相关。
临床怎么用
- M-TEER术后应综合评估残余MR程度和TMPG,而非仅关注MR减少。
- 对于MR≤轻度但TMPG≥5 mmHg的患者,需警惕主要终点风险升高。
- 中度残余MR但TMPG<5 mmHg的患者预后与MR≤轻度且TMPG<5 mmHg者相当,可能无需过度干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although reducing mitral regurgitation (MR) after mitral transcatheter edge-to-edge repair (M-TEER) improves outcomes, the impact of increased transmitral mean pressure gradient (TMPG) remains controversial. OBJECTIVES: This study aimed to evaluate the clinical significance of MR reduction and TMPG elevation in patients with functional mitral regurgitation (FMR) after M-TEER. METHODS: A total of 2,360 FMR patients were evaluated using postdischarge echocardiography after M-TEER. The relationship between TMPG and outcomes was assessed using spline analysis and group-based comparisons. Based on residual MR severity and TMPG, patients were categorized into 5 groups to assess the prognostic impact of postprocedural hemodynamics: MR ≤ mild and TMPG <5 mm Hg (n = 1,702), MR ≤ mild and TMPG ≥5 to <10 mm Hg (n = 164), moderate MR and TMPG <5 mm Hg (n = 361), moderate MR and TMPG ≥5 to <10 mm Hg (n = 71), and MR > moderate or TMPG 10 mm Hg (n = 62). The primary endpoint was all-cause death or heart failure hospitalization. RESULTS: The 2-year primary endpoint event rates increased progressively with higher TMPG, from 25.0% at 1 mm Hg to 47.0% at 6 mm Hg. In multivariable analysis, TMPG per 1 mm Hg increment was independently associated with the primary endpoint (HR: 1.10; 95% CI: 1.02-1.17; P = 0.008). Using MR ≤ mild as the reference, moderate MR was not linked to higher risk, whereas MR > moderate remained a significant predictor of primary endpoint. The patients with MR ≤ mild and TMPG <5 mm Hg had the lowest incidence of the primary endpoint among the 5 groups (28.4%, 39.0%, 33.0%, 43.7%, 48.4%; P < 0.001). However, event risk was not significantly different between patients with moderate MR and TMPG <5 mm Hg and those with MR ≤ mild and TMPG <5 mm Hg (HR: 1.13; 95% CI: 0.92-1.41; P = 0.24). Failure to achieve MR ≤ mild and TMPG <5 mm Hg was associated with larger left atrial volume index, greater effective regurgitation orifice area, elevated baseline TMPG, and old-generation G2 device use. CONCLUSIONS: In patients with FMR, elevated TMPG was consistently associated with higher risks of the primary endpoint. Mild or moderate residual MR with low TMPG was associated with more favorable prognosis, suggesting that balancing MR reduction and TMPG may help refine risk stratification after M-TEER. (Japanese Registry study of valvular heart diseases treatment and prognosis; UMIN000023653).
引用
- Tsunamoto H, Yamamoto M, Kagase A, et al. Using Transmitral Pressure Gradients and Residual Mitral Regurgitation to Optimize Outcome After Transcatheter Edge-to-Edge Repair. J Am Coll Cardiol. 2025. PMID: 41193089. doi:10.1016/j.jacc.2025.07.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。